Combined use of IN10018 and PLD
US12115160B2 · kind B2 · utility
0Cited by
1References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 24, 2023 |
| Grant date | Oct 15, 2024 |
| Priority date | — |
| Expiry date | Aug 24, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the combined use of: (a) the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) PLD or a pharmaceutically acceptable salt thereof, for treating ovarian cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.